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As discussed in the mini-monograph article on
trichloroethylene (TCE) pharmacokinetics
(Chiu et al. 2006b), exposure to TCE results in
a complex internal mixture of parent com-
pound and its metabolites [see Chiu et al.
(2006b) for a postulated metabolism scheme].
Many of these metabolites have been shown to
have toxicologic effects in TCE target organs,
and several hypotheses have been put forth as
to the “active” agent in TCE toxicity. Although
TCE exposure has been associated with a wide
array of adverse health effects, including neuro-
toxicity, immunotoxicity, developmental toxic-
ity, endocrine toxicity, and several forms of
cancer [see overview article by Chiu et al.
(2006a)], most of the mechanistic information
on TCE toxicity focuses on the liver and kid-
ney. For liver toxicity and/or carcinogenesis,
the TCE metabolites dichloroacetic acid
(DCA) and trichloroacetic acid (TCA), both
of which induce liver tumors in rodent labora-
tory studies, have been the major focus of
study as potential active agent(s). For TCE-
induced kidney effects, including cancer, glu-
tathione (GSH) conjugation products such as
S-(1,2-dichlorovinyl)-L-cysteine (DCVC) and
its bioactivation products, some of which may
be genotoxic and/or nephrotoxic (Lash et al.
2000), have been the major focus of study. An
alternative hypothesis relating to the formation
of formic acid has also been investigated (Dow
and Green 2000).
The U.S. Environmental Protection
Agency (EPA) 2001 draft TCE risk assessment
(U.S. EPA 2001) concluded that it is difﬁcult
to determine which TCE metabolites may be
responsible for liver and kidney tumorigenesis,
the key events involved in their modes of action
(MOAs), and the relevance of these MOAs to
humans. In this article we present a review of
the recent scientific literature on the MOAs
and effects of TCE metabolites that may be
related to TCE-induced liver and kidney
tumorigenesis in the context of these key ques-
tions. Although some scientiﬁc conclusions can
be drawn from this updated body of data, spec-
ulation as to the effect of these data on the ﬁnal
TCE risk assessment would be premature at
this point because of the ongoing National
Academy of Sciences consultation discussed in
the overview article (Chiu et al. 2006a) and the
subsequently planned revision of the EPA TCE
risk assessment. Therefore, the purpose here
and throughout this mini-monograph is to
review recently published scientiﬁc literature in
the context of how it informs the key scientiﬁc
issues believed to be most critical in developing
a revised risk assessment.
TCE Metabolites and
Liver Tumors
As discussed elsewhere in this mini-monograph
(Chiu et al. 2006a; Scott and Chiu 2006),
associations between TCE and liver tumors
have been reported in both laboratory and
epidemiologic studies. Three key issues with
respect to liver tumor induction are the rela-
tive importance of TCA and DCA in tumor
induction, the elucidation of key events in the
hypothesized MOAs, and the relevance of
TCE-, TCA-, and/or DCA-induced rodent
liver tumors to human risk. Substantial new
toxicologic data (although none on muta-
genicity) derived from studies of TCA,
DCA, and chloral hydrate (CH) inform all
these issues.
Dichloroacetic acid. As discussed in the
pharmacokinetics article in this mini-mono-
graph (Chiu et al. 2006b), direct evidence for
the formation of DCA from TCE is limited
because of the difﬁculty in directly detecting
DCA after TCE exposure. However, Bull
et al. (2002) have noted that DCA-induced
liver tumors have been observed at exposure
levels for which DCA cannot be detected
in vivo. In addition, indirect evidence sug-
gests that DCA is formed from TCE in vivo
and contributes to liver tumor development.
For instance, Schultz et al. (2002) and Bull
et al. (2004) reported that pretreatment with
either DCA or TCE inhibits the cytosolic
enzyme glutathione S-transferase (GST) ξ,
also known as maleylacetoacetate (MAA) iso-
merase, and TCA pretreatment does not.
TCE treatment at 1 g/kg decreased the Vmax
for DCA metabolism to 49% of control lev-
els, resembling effects of DCA treatment at
0.05 g/L (Schultz et al. 2002). The studies
discussed in this section note a variety of
DCA effects consistent with conditions that
increase liver cancer risk across species and
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9 May 2006]suggest pathologic changes induced by DCA
on whole liver consistent with changes
observed in preneoplastic foci from a variety
of agents.
A number of studies suggest DCA-
induced liver cancer may be linked to its
effects on GST-ξ, which is part of the tyrosine
catabolism pathway whose disruption in
type 1 hereditary tyrosinemia has been linked
to increased liver cancer risk in humans.
Specifically, GST-ξ metabolizes MAA to
fumarylacetoacetate (FAA), which displays
apoptogenic, mutagenic, aneugenic, and mito-
genic activities (Bergeron et al. 2003; Jorquera
and Tanguay 2001; Kim et al. 2000), and
FAA and MAA accumulation have been sug-
gested to increase cancer risk (Tanguay et al.
1996). Cornett et al. (1999) reported DCA
exposure in rats increased accumulation of
maleylacetone (a spontaneous decarboxylation
product of MAA), suggesting MAA accumula-
tion. Ammini et al. (2003) reported depletion
of GST-ξ to be exclusively a posttranscrip-
tional event and suggested that genetic abla-
tion of GST-ξ causes FAA and MAA
accumulation in mice. Schultz et al. (2002)
reported that DCA elimination is controlled
by liver metabolism via GST-ξ in mice and
that DCA inhibits its own metabolism, with
young mice being the most sensitive.
Conversely, older mice (60 weeks) overall had
a decreased capacity to eliminate DCA com-
pared with younger mice. The authors sug-
gested that exogenous factors that deplete or
reduce GST-ξ will decrease DCA elimination
and may increase its carcinogenic potency. In
humans, GST-ξ has also been reported to be
inhibited by DCA and to be polymorphic
(Blackburn et al. 2000, 2001; Tzeng et al.
2000). Board et al. (2001) reported one vari-
ant of GST-ξ to have significantly higher
activity with DCA as a substrate than other
isoforms, suggesting differential susceptibility.
Another area of investigation regarding the
MOA for DCA liver tumor induction has been
effects on glycogen and lipid metabolism.
Individuals with glycogen storage disease or
with poorly controlled diabetes have excessive
storage of glycogen in their livers (glycogenosis)
and increased risk of liver cancer (Adami et al.
1996; LaVecchia et al. 1994; Rake et al. 2002;
Wideroff et al. 1997). In an animal model
where hepatocytes are exposed to a local hyper-
insulinemia, insulin induces formation of
glycogenotic foci of altered hepatocytes (FAHs)
in liver acini that develop into hepatocellular
tumors (Evert et al. 2005). A number of stud-
ies have reported DCA-induced suppression of
apoptosis, decreases in insulin, and glycogeno-
sis in mouse liver at levels that also induce liver
tumors (Bull 2004; Bull et al. 2004; Lingohr
et al. 2001). Lingohr et al. (2002) reported that
DCA-induced glycogenosis in isolated murine
hepatocytes was dose related, occurred at very
low doses (10 µM), occurred without the pres-
ence of insulin, was not affected by insulin
addition, was dependent on phosphatidylinosi-
tol 3-kinase activity, and was not a result of
decreased glycogen breakdown. The authors
noted that phosphatidylinositol 3-kinase is also
known to regulate cell proliferation and apop-
tosis in hepatocytes and that understanding
these mechanisms may be important to under-
standing DCA-induced carcinogenesis. They
also reported that insulin receptor (IR) protein
levels decreased to 30% of controls in mouse
liver after up to 52 weeks of DCA treatment.
Activation of the IR is also the principal path-
way by which insulin stimulates glycogen syn-
thetase (the rate-limiting enzyme of glycogen
biosynthesis). However, although DCA-
induced liver tumors were glycogen poor, both
IR protein and phosphorylation of mitogen-
activated protein kinase (a downstream target
protein of the IR) were elevated (Lingohr et al.
2001). The authors suggested that normal
hepatocytes down-regulate insulin-signaling
proteins in response to the accumulation of
liver glycogen caused by DCA and that the ini-
tiated cell population, which does not accumu-
late glycogen and is promoted by DCA
treatment, responds differently from normal
hepatocytes to the insulin-like effects of DCA.
Glycogenosis and overexpression of pro-
teins affected by the IR in preneoplastic foci
are generalized responses that have been
reported to be induced by a variety of agents.
Nehrbass et al. (1998, 1999) reported that
focal overexpression of IR substrate 1, a mul-
tisite docking protein occupying a central
position in signaling cascades stimulated by a
number of growth factors, including insulin,
is an early event in hepatocarcinogenesis
closely correlated with preneoplastic hepatic
glycogenosis. IR substrate 1 is gradually
down-regulated during progression of these
lesions to a glycogen-poor neoplastic pheno-
type. Bannasch (2001) and Bannasch et al.
(2001) describe the early phenotypes of pre-
neoplastic foci induced by many oncogenic
agents (DNA-reactive chemicals, radiation,
viruses, transgenic oncogenes, and local
hyperinsulinism) as insulinomimetic. Thus,
the response of liver to DCA (glycogenosis
with emergence of glycogen-poor tumors) is
similar to the progression of preneoplastic foci
to tumors induced from a variety of agents
and conditions associated with increased can-
cer risk. Finally, Bull et al. (2002) reported
that expression of IR was elevated in tumors
of control mice or mice treated with TCE,
TCA, and DCA but not in nontumor areas,
which is consistent with this effect being non-
speciﬁc to DCA.
Emerging studies of DCA-induced gene
expression changes show alteration of a number
of genes identified with cell growth, tissue
remodeling, apoptosis, cancer progression, and
xenobiotic metabolism in mouse liver at high
drinking water doses (2 g/L DCA) (Thai et al.
2001, 2003). After 4 weeks, RNA expression
was altered in four known genes [α1 protease
inhibitor 3, cytochrome b5, stearoyl–CoA
desaturase exon 6, and carboxylesterase] in two
mice (Thai et al. 2001). Except for CoA desat-
urase, a similar pattern of gene change was
reported in DCA-induced tumors (10 tumors
from 10 different mice) after 93 weeks. Using
cDNA microarray in the same mice, Thai et al.
(2003) identiﬁed 24 genes with altered expres-
sion, 15 of which were conﬁrmed by Northern
blot analysis after 4 weeks of exposure. Of the
15 genes, 14 revealed expression suppressed 
2- to 5-fold: MHR 23A, cytochrome P450
(CYP) 2C29, CYP3A11, serum paraoxonase/
arylesterase 1, liver carboxylesterase, α1 anti-
trypsin,  ER p72,  GST-π1, angiogenin,
vitronectin precursor, cathepsin D, plasmino-
gen precursor (contains angiostatin), prothrom-
bin precursor, and integrin α3 precursor.
Additional genes, CYP2A4/5, had a 2-fold ele-
vation in expression. After 93 weeks of treat-
ment with 3.5 g/L DCA, Northern blot
analyses of total RNA isolated from DCA-
induced hepatocellular carcinomas showed
similar alteration of expression (11 of 15).
Interestingly, while genes involved in glycogen
or lipid metabolism were not tested, the authors
report no change in peroxisome proliferator–
activated receptor α (PPARα) and IR gene
expression [see Keshava and Caldwell (2006)
for additional discussion of PPARα]. Although
these studies do document genetic expression
changes, a key event speciﬁc for DCA induc-
tion of tumors was not identiﬁed.
Tumor phenotypes and the roles of TCA
and DCA. Bull et al. (2002) reported that
TCE-induced liver tumors in mice have phe-
notypic characteristics of both DCA- and
TCA-induced tumors (i.e., a mixture of phe-
notypes with some tumors c-jun positive,
some tumors c-jun negative, and some tumors
displaying both). TCA-induced tumors did
not stain with this antibody, whereas a num-
ber of DCA-induced tumors did. Moreover,
mutation frequencies of the H-ras codon in
TCE-induced tumors (1 g/kg/day) differed
signiﬁcantly from those induced by TCA (0.5
or 2 g/L), with DCA-induced tumors (0.5 or
2 g/L) intermediate between values obtained
with TCA and TCE. The authors suggested
that these data are not consistent with the
hypothesis that all liver tumors induced by
TCE are produced by TCA alone. However,
use of the tumor phenotype to assign the
MOA is less clear.
Although Bull et al. (2004) have suggested
that the negative expression of c-jun in TCA-
induced tumors may be consistent with a char-
acteristic phenotype shown in general by
peroxisome proliferators as a class, no evidence
exists to support this. Tumors and foci induced
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chondrial proliferation and mitochondrial
enzymes (thyromimetic rather than insuli-
nomimetic) (Keshava and Caldwell 2006). The
studies cited in Bull et al. (2004) do not exam-
ine TCA-induced tumors for these properties.
In addition, Bull et al. (2002) reported that
TCA-induced tumors had a mutation fre-
quency and spectrum of H-ras similar to those
of historical controls, and the peroxisome pro-
liferators ciproﬁbrate and methyl clofenapate
caused lower ras mutation frequencies in mice.
Miller et al. (1995) reported that “basophilic”
preneoplastic lesions induced by the peroxi-
some proliferator Wyeth-14,643 (WY) alone
or those initiated by N-nitrosodiethylamine
and WY together do not express transforming
growth factor(TGF)-α , whereas Bannasch
(1996) reports increased TGF-α expression in
preneoplastic lesions from agents other than
peroxisome proliferators.
In addition, use of the term “basophilic” in
describing preneoplastic foci or tumors can be
misleading. The different types of FAHs have
been related to three main preneoplastic hepa-
tocellular lineages: the glycogenotic–basophilic
cell lineage, its xenomorphic–tigroid cell vari-
ant, and the amphophilic–basophilic cell
lineage. Speciﬁc changes of the cellular pheno-
type of the ﬁrst two FAH lineages are similar in
experimental and human hepatocarcinogenesis
regardless of whether they are elicited by DNA-
reactive chemicals, hormones, radiation, viruses,
transgenic oncogenes, or local hyperinsulinism
as described by the first two FAHs, and this
similarity favors extrapolation of data obtained
in animals to humans (Bannasch et al. 2001,
2003; Su and Bannasch 2003). In contrast, the
amphophilic cell lineage of hepatocarcino-
genesis has been observed mainly after rodents
have been exposed to peroxisome proliferators
or to Hepadnaviridae (Bannasch et al. 2001).
However, a recent study of di(2-ethylhexyl)
phthalate (DEHP) reported the majority of
liver FAHs to be of the first two types (Voss
et al. 2005) after a lifetime of exposure to
DEHP with a dose-related tendency for
increased numbers of amphophilic FAHs.
Bannasch (1996) described amphophilic
FAHs and tumors induced by peroxisome pro-
liferators to maintain the phenotype as the foci
progress to tumors. They are glycogen poor
from the start with increased numbers of mito-
chondria, peroxisomes, and ribosomes. The
author further stated that other researchers’
“homogenous basophilic” descriptions of foci
induced by WY are really amphophilic. Agents
other than peroxisome proliferators can induce
acidophilic or eosinophilic (due to increased
smooth endoplasmic reticulum) or glyco-
genotic foci, which tend to progress to baso-
philic stages (due to increased ribosomes).
Descriptions of tumors induced by TCA and
DCA are consistent with this progression.
Indeed, Pereira (1996) described the FAHs
and tumors induced by DCA to be eosino-
philic at higher exposure levels but, at lower or
intermittent exposures, to be half eosinophilic
and half basophilic. Regardless of exposure
level, half the TCA-induced foci were eosino-
philic, and half were basophilic, with tumors
75% basophilic. In control animals, the lim-
ited numbers of lesions were mostly basophilic;
the rest were eosinophilic with the exception of
a few mixed tumors.
Carter et al. (2003) examined the pheno-
type of liver tumors induced by DCA in mice
and the shape of the dose–response curve for
insight into its MOA. They reported a dose
response of histopathologic changes (all classes
of premalignant lesions and carcinomas)
occurring in the livers of mice receiving from
0.05 to 3.5 g/L DCA for 26–100 weeks and
suggested that foci and adenomas demon-
strated neoplastic progression with time at
lower doses than observed for DCA genotoxic-
ity. Preneoplastic lesions were identified as
eosinophilic, basophilic, and/or clear cell
(grouped with clear cell and mixed cell) and
dysplastic. Altered foci were 50% eosinophilic
with about 30% basophilic. As foci became
larger and evolved into carcinomas, they
became increasingly basophilic. The pattern
held true throughout the exposure range. An
increase in atypical nuclei related to dose and
length of exposure was also observed in “non-
involved” liver. Glycogen deposition was also
dose dependent with periportal accumulation
in mice administered 0.5 g/L DCA. The ﬁnd-
ings are consistent with those of DeAngelo
et al. (1999), who reported hepatocarcino-
genicity at the lowest dose tested (0.05 g/L
DCA or 8 mg/kg/day) and concluded that
induction of liver cancer did not appear to be
conditional on peroxisome proliferation
(which was significantly increased only at
much higher concentrations) or chemically
sustained cell proliferation.
DNA hypomethylation by TCA and DCA.
Aberrant DNA methylation has emerged in
recent years as a common hallmark of all types
of cancers, with hypermethylation of the pro-
moter region of speciﬁc tumor suppressor genes
and DNA repair genes leading to their silencing
(an effect similar to their mutation) and
genomic hypomethylation (Ballestar and
Esteller 2002; Berger and Daxenbichler 2002;
Herman et al. 1998; Pereira et al. 2004; Rhee
et al. 2002). Whether DNA methylation is a
consequence or cause of cancer is a long-stand-
ing issue (Ballestar and Esteller 2002). Fraga
et al. (2004, 2005) reported global loss of
monoacetylation and trimethylation of histone
H4 as a common hallmark of human tumor
cells; they suggested, however, that genomewide
loss of 5-methylcytosine (associated with the
acquisition of a transformed phenotype) exists
not as a static predeﬁned value throughout the
process of carcinogenesis but rather as a
dynamic parameter (i.e., decreases are seen early
and become more marked in later stages).
A body of work has also emerged regard-
ing the hypothesis that toxicity of TCE and
its metabolites may arise from its effects on
DNA methylation status, although little is
known as to the mechanism(s) by which this
occurs. Tao et al. (2000) have reported that
DCA (500 mg/kg), TCA (500 mg/kg), and
TCE (1,000 mg/kg) decreased methylation of
DNA and the promoter region of the pro-
tooncogenes c-myc and c-jun after 5 days of
exposure in mouse liver. Increased levels of
mRNA and protein for c-myc and c-jun were
also reported after DCA and TCA treatment.
Ge et al. (2001) reported DCA- and TCA-
induced DNA hypomethylation and cell pro-
liferation in the liver of female mice dosed at
500 mg/kg and decreased methylation of the
c-myc promoter region in the liver, kidney,
and urinary bladder. However, increased cell
proliferation preceded hypomethylation.
Hypomethylation of the c-myc gene in the liver
has also been reported after exposure to the
peroxisome proliferators 2,4-dichlorophen-
oxyacetic acid (1,680 ppm), dibutyl phthalate
(20,000 ppm), gemﬁbrozil (8,000 ppm), and
WY (50–500 ppm, with no effect at 5 or
10 ppm) after 6 days in the diet (Ge et al.
2002). Although WY was much more potent
as an inducer of cell proliferation and peroxi-
some proliferation than the other compounds
tested, WY-induced hypomethylation was
only slightly greater. Thus, the hypomethyla-
tion does not appear to be a chemical-speciﬁc
effect at these concentrations.
After initiation by N-methyl-N-nitrosourea
(25 mg/kg) and exposure to 20 mmol/L DCA
or TCA (46 weeks), Tao et al. (2004) reported
similar hypomethylation of total mouse liver
DNA by DCA and TCA with tumor DNA
showing greater hypomethylation. A similar
effect was noted for differentially methylated
region 2 of the insulin-like growth factor 2
(IGF2) gene The authors suggested that
hypomethylation of total liver DNA and the
IGF2 gene found in nontumorous liver tissue
would appear to be the result of a more pro-
longed activity and not cell proliferation,
whereas hypomethylation of tumors could 
be an intrinsic property of the tumors.
Overexpression of the IGF2 gene in liver
tumors and preneoplastic foci has been shown
in both animal models of hepatocarcinogenesis
and humans and may enhance tumor growth,
acting via the overexpressed IGF2 receptor
(Scharf et al. 2001; Werner and Le Roith
2000). IGF1 is the major mediator of growth
hormone effects; it thus has a strong inﬂuence
on cell proliferation and differentiation and is a
potent inhibitor of apoptosis (Furstenberger
and Senn 2002). Normally, expression of
MOAs of TCE metabolites
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period than in the adult but is overexpressed in
human hepatocarcinomas because of activation
of fetal promoters (Scharf et al. 2001) and loss
of imprinting (Khandwala et al. 2000). Takeda
et al. (1996) reported that IGF2 expression in
the liver is monoallelic (maternally imprinted)
in the fetal period, is relaxed during the post-
natal period (resulting in biallelic expression),
and is imbalanced in human hepatocarcinomas
(leading to restoration of monoallelic IGF2
expression).
However, Bull (2004) and Bull et al.
(2004) have recently suggested that hypo-
methylation and peroxisome proliferation
occur at higher exposure levels than those that
induce liver tumors for TCE and its metabo-
lites and that, therefore, these effects may not
be key events in liver tumorigenesis. They
reported that a direct comparison in the no-
effect level or low-effect level for liver tumor
induction in the mouse and several other end
points shows that for TCA, liver tumors occur
at lower concentrations than peroxisome pro-
liferation in vivo but that PPARα activation
occurs at a lower dose than either tumor for-
mation or peroxisome proliferation. A similar
comparison for DCA shows that liver tumor
formation occurs at a much lower exposure
level than peroxisome proliferation, PPARα
activation, or hypomethylation. However,
apoptosis is suppressed at levels of DCA expo-
sure that also induce liver tumors as well as
decreases in insulin and increases in glycogen.
In addition, they reported that these chemicals
are effective as carcinogens at doses that do not
produce cytotoxicity.
Chloral hydrate. A large fraction of TCE
oxidative metabolism appears to go through
CH, with subsequent metabolism to TCA and
trichloroethanol (TCOH) (Chiu et al. 2006b).
The recent studies of CH toxicity are consistent
with the general presumption that oxidative
metabolites are important for TCE-induced
liver tumors, but whether CH and its metabo-
lites are sufﬁcient to explain all of TCE liver
tumorigenesis remains unclear, particularly
because of uncertainties regarding how DCA
may be formed (Chiu et al. 2006b).
Recent studies of CH have been reported
that may enable a comparison between toxicity
of TCE and CH and may help elucidate its role
in TCE effects. However, it is important to
examine the strengths and weaknesses of such
studies as well as their consistency and inconsis-
tency with some of the proposed MOAs for
TCE or its other metabolites. George et al.
(2000) exposed male B6C3F1 mice and male
F344/N rats to CH in drinking water for
2 years (up to 162.6 mg/kg/day). The authors
considered all neoplastic lesions observed in the
kidneys, spleen, and testes to be spontaneous
for the male F344 rat and male B6C3F1 mouse
based on historical controls, but data were not
shown. In mice, preneoplastic foci and adeno-
mas were increased in the livers of all CH treat-
ment groups (13.5–146.6 mg/kg/day) at
104 weeks, the number of carcinomas was
increased at the highest dose, and time to
tumor decreased in all CH treatment groups.
CH exposure did not alter serum chemistry,
hepatocyte proliferation, or hepatic palmi-
toyl–CoA oxidase (an enzyme associated with
PPARα agonism) in rats and mice at any of the
time periods monitored. Study limitations
included the following: only ﬁve animals were
examined at the high dose, thereby limiting the
study’s power to determine an effect; control
mice had a high spontaneous carcinoma rate
(54%), thereby limiting the ability to detect a
treatment-related response; and no descriptions
of the foci or tumor phenotype were given.
Leakey et al. (2003) studied the effects of
CH exposure (0, 25, 50, and 100 mg/kg,
5 days/week, 104–105 weeks via gavage) in
male B6C3F1 mice with dietary control used to
manipulate body growth. Dietary control
decreases background liver tumor rates (inci-
dence of 15–20%) and is associated with
decreased variation in liver-to-body weight
ratios, thereby potentially increasing assay sensi-
tivity. In dietary-controlled groups and groups
fed ad libitum, liver adenomas and carcinomas
(combined) were increased with overall tumor
incidence reduced, and time to tumor increased
after dietary control. In the dietary-restricted
group administered 100 mg/kg CH, of the
enzymes associated with PPARα agonism (total
CYP, CYP2B isoform, CYP4A, or lauric acid
ω-hydroxylase activity), only CYP4A and lauric
acid ω-hydroxylase activity were increased at
15 months of exposure. No descriptions of liver
pathology were given. Seng et al. (2003)
described CH toxicokinetics in mice at doses
up to 1,000 mg/kg/day for 2 weeks with dietary
control and caloric restriction slightly reducing
acute toxicity. Lauric acid ω-hydroxylase and
palmitoyl–CoA fatty acid hydroxylase (another
enzyme associated with PPARα agonism) were
induced only at doses > 100 mg/kg in all
groups, with dietary-restricted mice showing
the greatest induction. Differences in serum lev-
els of TCA, the major metabolite remaining
24 hr after dosing, did not correlate with
hepatic lauric acid ω-hydroxylase activities
across groups.
Ho et al. (2003) measured urinary iso-
prostan 8-epi-prostaglandin F2α, a marker of
whole-body lipid peroxidation, and serum
tumor necrosis factor (TNF)-α after admin-
istering injections of 100 mg/kg CH in corn
oil to rats. A 5-fold elevation of 8-epi-
prostaglandin F2α was observed on day 1, and
serum TNF-α was elevated about 7-fold on
day 2. Concurrent treatment with vitamin E
(100 mg/kg) reduced the effects of CH treat-
ment. In the same study, CH induced greater
cytotoxicity but less apoptosis in human
Chang liver cells than in human lymphocytes
in vitro. The authors suggested a temporal
relationship between lipid peroxidation and
TNF-α induction in the rat and differential
susceptibility between liver and extrahepatic
tissue from these results.
TCE Metabolites and Kidney
Tumors
As was the case for liver tumors, associations
between TCE and kidney tumors have been
reported in both laboratory and epidemiologic
studies (Chiu et al. 2006a; Scott and Chiu
2006). Studies of TCE-induced kidney
tumorigenesis have concentrated mostly on
metabolites formed in the GSH conjugation
pathway of TCE metabolism. Under this set
of hypotheses, DCVC, which is formed by
γ-glutamyltransferase metabolism of the TCE
GSH conjugate S-(1,2-dichlorovinyl)-L-glu-
tathione, is thought to exert tumorigenic
responses either directly or through bioactiva-
tion to reactive species in the kidney (Lash
et al. 2003, 2005; Chiu et al. 2006b). Dow
and Green (2000) have suggested an alterna-
tive mechanism of nephrotoxicity by which
the oxidative TCE metabolites TCA and
TCOH interact with vitamin B12 through a
free radical mechanism to induce a B12 deﬁ-
ciency, leading to excessive formic acid.
Substantial new toxicologic data derived from
studies of DCVC and TCOH have emerged
that may inform three key issues concerning
the MOA for TCE-induced kidney tumors:
an understanding of whether cytotoxicity
plays a role in tumorigenesis, determination of
the source(s) of cytotoxicity, and elucidation
of species differences in susceptibility.
S-(1,2-Dichlorovinyl)-L-cysteine. DCVC
has been used as a model compound in the
study of proximal tubular (PT) cell injury
(Nony and Schnellmann 2003; Vaidya et al.
2003a, 2003b, 2004) and also has been
shown to induce effects on cell signaling at
lower concentrations than cytotoxicity.
As a result of acute chemical insult, PT
cells undergo mitochondrial dysfunction, ATP
depletion, impaired solute and ion transport,
loss of cell polarity, cytoskeletal disruption, and
a variety of other effects. Injured PT cells that
do not die or detach from the basement mem-
brane are thought to contribute to regeneration
of the tubular epithelium and to proliferate
(Nony and Schnellmann 2003). Vaidya et al.
(2003a, 2003b) reported PT necrosis after a
single intraperitoneal (ip) injection of DCVC
and mortality at doses of 40 mg/kg and
greater; they also reported that prior exposure
to DCVC (15 mg/kg, ip, for 72 hr) or mer-
curic chloride (6 mg/kg) was protective from
DCVC-induced lethality after a second expo-
sure (75 mg/kg, ip) in male mice. Vaidya et al.
(2004) suggested that sustained stimulation of
the renal extracellular-signal–related kinase
Caldwell and Keshava
1460 VOLUME 114 | NUMBER 9 | September 2006 • Environmental Health Perspectivespathway may have been a key factor in
reported protection from acute DCVC toxic-
ity. These studies show effects of DCVC
in vivo but are of limited use in determining
the potential MOA of kidney cancer induction
reported in rats and epidemiology studies in
humans (Scott and Chiu 2006) given the
choice of a species insensitive to kidney tumor
formation (mice) and the high doses used.
Using an in vitro model of primary cul-
tures of PT and distal tubular (DT) rat kid-
ney cells, Cummings et al. (2000) reported
that unlike TCE, DCVC (0.1–1 mM) was
highly cytotoxic in both PT and DT cells
from short-term (3 hr) or long-term (72 hr)
incubations, with DT cells having greater
DCVC sensitivity after prolonged incuba-
tions. The authors suggested that PT cells are
more susceptible to DCVC toxicity in vivo
because they are ﬁrst exposed to DCVC and
have efficient transport into the cell. Chen
et al. (2001) reported DCVC-induced apop-
tosis and mitochondrial effects in cultured
porcine PT cells at similar concentrations
(0.5 mM). However, Lash et al. (2001)
reported that DCVC caused apoptosis and
enhanced cell proliferation in primary cul-
tures of human PT (hPT) cells at environ-
mentally relevant doses and at earlier time
points and lower concentrations than those
that caused necrosis. The hPT cells from
males were modestly more sensitive to
DCVC-induced necrosis than were those
from females (100 µM DCVC at 1 hr vs.
200 µM at 8 hr) with no sex-dependent
change in apoptosis (10 µM at 2 hr). After a
24-hr treatment with as little as 10 µM
DCVC, a small increase was also noted in the
percentage of cells in S-phase, suggesting that
cell proliferation was stimulated. The authors
suggested that although rat PT cells may be
more susceptible to DCVC-induced necrosis
than humans, the opposite pattern is true for
DCVC-induced apoptosis.
Lash et al. (2005) reported that DCVC
altered hPT cell expression of proteins related
to apoptosis (Apaf-1, αBax, αPARP, Bcl-2, cas-
pase-9), cell growth (c-jun, Hsp27, p53), and
oxidative stress response (NF-κB p65 subunit),
with patterns that are complex and dependent
on concentration and exposure time. All types
of proteins exhibited at least 200% increases at
10-µM concentration within 24 hr of incuba-
tion. Apoptosis was decreased at higher DCVC
concentrations as necrosis was induced. Nony
and Schnellmann (2001, 2003) reported 50%
lethality in rabbit PT cells exposed to higher
concentrations (200 µM DCVC), with surviv-
ing cells exhibiting irreversible inhibition of
physiologic function. Addition of pharmaco-
logic concentrations of L-ascorbic acid-2-phos-
phate that promote repair and proliferation,
collagen IV that promotes repair of function
but not proliferation, and other extracellular
matrix proteins (ﬁbronectin, laminin, and col-
lagen I) had no effect. Nowak (2003) reports
25% rabbit PT cell death using the same
model and decreased protein kinase C activity,
mitochondrial function, and active Na+ trans-
port. Van de Water et al. (2001) reported focal
adhesion kinase in a porcine PT cell line
(LLC-PK1) to be important in DCVC-
induced apoptosis and concluded that loss of
focal adhesion kinase activity results in pertur-
bations of focal adhesion organization with
subsequent inactivation of associated signaling
molecules and loss of survival signal. Thus, sev-
eral signaling pathways appear to be activated
in response to DCVC that are dependent on
time and exposure concentration as necrosis,
apoptosis, or proliferation is induced.
DCVC can also be metabolized by the
ﬂavin-containing monooxygenase (FMO) sys-
tem to produce DCVC sulfoxide (DCVCS),
which is highly reactive and more nephrotoxic
in rat PT cells than DCVC alone and plays a
prominent role in effects on hPT cells (Lash
et al. 2001, 2003). Lash et al. (2003) reported
DCVCS-induced necrosis (200 µM at 48 hr)
and apoptosis (within 1 hr at 10 µM expo-
sure) in hPT cells, suggesting that DCVC
bioactivation and cytotoxicity are more β-lyase
dependent than FMO dependent at lower
doses and early stages of exposure. Krause
et al. (2003) reported polymorphism in FMO
that may indicate a wide range of susceptibil-
ity to DCVCS in the human population.
Trichloroethanol. Green et al. (2003,
2004) have investigated the hypothesis that
formate formation from the TCE oxidative
metabolite TCOH is a key event for TCE kid-
ney effects; however, they have not provided
much additional support because of data limi-
tations and inconsistencies between reported
effects of TCOH and those of TCE. Green
et al. (2003) reported no dose response in for-
mate levels in male Fischer rats after 4 weeks
of exposure to TCOH in drinking water at 0,
0.5, and 1.0 g/L, so the lower dose was
reduced to 0.35 g/L and folate was added to
the drinking water for the rest of the 53-week
exposure period. The authors suggested that
these TCOH doses would result in formate
levels of 0.5 g/L or greater (the upper range of
TCE exposure levels in cancer bioassays).
Using this paradigm, urinary formate levels
were elevated at the two doses examined,
peaking at 12 weeks of exposure, before
declining, and were associated with decreased
pH. Kidney-to-body weight ratios decreased
throughout the time course of the study, with
a smaller decrease in rats receiving TCOH at
the highest level. Urinary N-acetyl glucosami-
nadase (NAG) levels were used as a marker of
kidney damage along with creatinine, protein,
alkaline phosphatase, and γ-glutamyl trans-
ferase. Only NAG was sporadically elevated
throughout the study in both dose groups,
with protein levels increasing at earlier time
points. The authors reported some increase in
cell replication in areas of the kidney at the
highest dose at 29 weeks but not at 40 weeks.
They also reported that kidneys showed treat-
ment-related increases in α2µ-globulin (an
effect not observed with TCE treatment)
along with hyaline droplet accumulation and
basophilia between 16 and 18 weeks but gave
no quantitative analyses. By 40 weeks, tubular
degeneration (increased eosinophilia, tubular
vacuolation, and intratubular cast formation)
was reported at the highest dose along with
increased hyaline droplet accumulation and
α2µ-globulin. By 52 weeks, these changes
were no longer apparent, but foci of “atypical”
tubule hyperplasia were reported in two rats in
each TCOH-treated group. No tumors or
preneoplastic foci were reported (unlike for
TCE, which induces kidney tumors). The
authors suggested that the pathologic changes
reported with TCOH exposure were consis-
tent with those exhibited by aged rats (chronic
progressive nephropathy) and that increases in
α2µ-globulin were not sufficient to account
for hyaline droplet increases.
Green et al. (2004) examined kidney func-
tion in workers occupationally exposed to
TCE and tried to relate it to TCOH toxicity.
Estimates of TCE exposure levels were extrap-
olated from TCA levels in the urine that var-
ied widely (range, 1–505 mg/L TCA). TCOH
was also measured with a wide range of
TCOH/TCA ratios between individuals
(range, 0.6–20.1). In unexposed and TCE-
exposed workers, a difference was observed in
NAG, urinary albumin, and formate (2-fold
increase over control levels) but not in other
markers of urinary toxicity (α1µ- and
β2µ-globulins, retinol binding protein, total
protein, or GST-α). A positive correlation was
reported between TCA urine levels and
GST-α but not NAG or albumin, in the
TCE-exposed population. A correlation
between formate and TCA and GST-α levels
was reported. The authors did not present cor-
relations between any parameters and urinary
TCOH; thus, any inferences between TCOH
concentration and toxicity are indirect.
Interestingly, the mean concentration (as mea-
sured by milligrams per gram creatinine) of
urinary TCA (72 ± 84 mg/g) was higher than
that of formate (9.45 ± 4.78 mg/g) in the
TCE-exposed group.
Summary
The studies reviewed here on effects of TCE
metabolites provide important insights into
TCE-induced liver and kidney tumorigenesis.
A number of the studies suggest that both DCA
and TCA contribute to TCE-induced liver
tumors and that many DCA effects are consis-
tent with conditions that increase liver cancer
risk and with changes in neoplasia. Studies of
MOAs of TCE metabolites
Environmental Health Perspectives • VOLUME 114 | NUMBER 9 | September 2006 1461DCVC and its bioactivation products have
revealed a number of different possible cell sig-
naling effects that may be related to kidney
tumorigenesis at lower concentrations than
those that produce cytotoxicity in the kidney.
Although MOAs and key events for TCE-
induced liver and kidney tumors have yet to be
definitely established, most of the studies
described here suggest that multiple metabolites
may contribute to liver and kidney tumorigene-
sis through a number of MOAs, none of which
appear to be irrelevant to humans.
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